Mary Beckerle - Johnson Johnson Independent Director

JNJ
 Stock
  

USD 170.67  0.49  0.29%   

  Director
Dr. Mary C. Beckerle, Ph.D., is an Independent Director of the Company. She has served as CEO of Huntsman Cancer Institute at the University of Utah since 2006. She is the associate vice president for cancer affairs and a distinguished professor of biology and oncological sciences at the University of Utah. Dr. Beckerle joined the faculty of the University of Utah in 1986 and currently holds the Jon M. Huntsman Presidential Endowed Chair. Dr. Beckerle has served on the National Institute of Health Advisory Committee to the Director, on the Board of Directors of the American Association for Cancer Research, as president of the American Society for Cell Biology, and as the Chair of the American Cancer Society Council for Extramural Grants. She currently serves on a number of scientific advisory boards, including the Medical Advisory Board of the Howard Hughes Medical Institute, and the Scientific Advisory Boards of the National Center for Biological Sciences at the Tata Institute of Fundamental Research in India, the Mechanobiology Institute in Singapore, and the Dana FarberHarvard Cancer Center. Dr. Beckerle held a Guggenheim Fellowship at the Curie Institute in Paris, received the Utah Governors Medal for Science and Technology in 2001, the Sword of Hope Award from the American Cancer Society in 2004 and is an elected Fellow of the American Academy of Arts and Sciences and the American Philosophical Society. Dr. Beckerle was also named a National Association of Corporationrationrate Directors Governance Fellow in 2012.
Age: 66  Director Since 2015      
732 214-0332  www.jnj.com

Johnson Johnson Management Efficiency

Johnson Johnson has Return on Asset of 8.9 % which means that on every $100 spent on asset, it made $8.9 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 25.17 %, implying that it generated $25.17 on every 100 dollars invested. Johnson Johnson management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Sales is estimated to increase to 0.26, while Return on Investment is projected to decrease to 22.01. Johnson Johnson Liabilities Non Current is increasing as compared to previous years. The last year's value of Liabilities Non Current was reported at 62.77 Billion. The current Tax Liabilities is estimated to increase to about 17.4 B, while Total Liabilities is projected to decrease to under 108 B.
The company has 32.6 B in debt with debt to equity (D/E) ratio of 0.43, which is OK given its current industry classification. Johnson Johnson has a current ratio of 1.39, which is typical for the industry and considered as normal. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Yoseph BornsteinMicrobot Medical
2016
David SchlachetBrooklyn Immunotherapeutics
2014
William HarrisonMerck Company
2009
Kathy WardenMerck Company
2020
Robert EckertAmgen Inc
2016
Craig ThompsonMerck Company
2008
Robert AlpernAbbvie Inc
2013
Brett HartAbbvie Inc
2016
Carolyn BertozziEli Lilly And
2017
Mary CoeMerck Company
2019
John NoseworthyMerck Company
2017
Vicki SatoBristol-Myers Squibb
2017
Jamere JacksonEli Lilly And
2016
Laurie GlimcherBristol-Myers Squibb
N/A
Frank BiondiAmgen Inc
2002
Francois CarbonnelAmgen Inc
2008
Karen VousdenBristol-Myers Squibb
2018
Fernando FernandezBiocardia
2016
Carlos RepresasMerck Company
2009
Jackson TaiEli Lilly And
2013
Don BaileyBrooklyn Immunotherapeutics
2019
Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 141700 people. Johnson Johnson (JNJ) is traded on New York Stock Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 141,700 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Nadja West, Independent Director
Darius Adamczyk, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Vanessa Broadhurst, Executive Vice President Global Corporate Affairs
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Mathai Mammen, Executive Vice President Pharmaceuticals, R&D
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
William Hait, Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer
James Swanson, Executive Vice President, Chief Information Officer
D Davis, Independent Director
Hubert Joly, Independent Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consumer Health
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Johnson Johnson without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Johnson Johnson using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Johnson Johnson information on this page should be used as a complementary analysis to other Johnson Johnson's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Johnson Stock analysis

When running Johnson Johnson price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Is Johnson Johnson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine Johnson Johnson value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.